Biolegend, 423107, Zombie UV™ Fixable Viability Kit
100tests
Catalog Number: 423107
Send an RFQ.
Category
Pack Size1 vial
Loading…
| Preparation | Zombie UV™ Fixable Viability kit is composed of lyophilized Zombie UV™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie UV™ dye until fully dissolved. 100 tests = 1 vial of Zombie UV™ + DMSO, 500 tests = 5 vials of Zombie UV™ + DMSO. |
|---|---|
| Storage & Handling | Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie UV™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type. |
| Excitation Laser | Ultraviolet Laser (355 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Zombie UV™ dye is excited by the UV laser (355 nm) and has fluorescence emission maximum at 459 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie UV™ dye has similar emission to DAPI. Standard Cell Staining Protocol: Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie UV™ dye and mix until fully dissolved Wash cells with PBS buffer (no Tris buffer and protein free). Dilute Zombie UV™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie UV™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA. Continue performing antibody staining procedure as desired. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation. No-wash Sequential Staining Protocol: Wash cells with PBS buffer (no Tris buffer and protein free). For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie UV™ dye and mix until fully dissolved Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie UV™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie UV™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie UV™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells. Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie UV™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie UV™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie UV™. |
| Application References(PubMed link indicates BioLegend citation) | Souza-Fonesca-Guimaraes F, et al. 2015. PNAS. 112:2376. PubMed |
|---|
| Product Citations | Souza-Fonseca-Guimaraes F, et al. 2016. Cell Death Dis. 7:e2302. PubMed Zgair A, et al. 2017. Sci Rep. . 10.1038/s41598-017-15026-z. PubMed Arruda DC, et al. 2022. J Control Release. 350:228. PubMed Michaels YS, et al. 2022. Sci Adv. 8:eabn5522. PubMed Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed Bonadonna M, et al. 2022. Sci Adv. 8:eabq4469. PubMed Humphries DC, et al. 2023. Front Immunol. 14:1100161. PubMed Heng Y, et al. 2023. J Transl Med. 21:167. PubMed Yi X, et al. 2023. Signal Transduct Target Ther. 8:107. PubMed Gu XW, et al. 2023. Nat Commun. 14:1439. PubMed Arunachalam PS, et al. 2023. J Clin Invest. 133:. PubMed Hackerova L, et al. 2023. Front Vet Sci. 10:1116891. PubMed Kak G, et al. 2023. J Neuroinflammation. 20:114. PubMed Lin W, et al. 2023. Commun Biol. 6:447. PubMed Borbet TC, et al. 2023. iScience. 26:106810. PubMed Wang X, et al. 2023. Stem Cell Rev Rep. . PubMed Argüello RJ, et al. 2020. Cell Metab. 32:1063. PubMed Reyes RA, et al. 2021. PLoS One. 16:e0261656. PubMed Rosina M, et al. 2022. Cell Metab. 34:533. PubMed Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed Klapholz M, et al. 2022. J Pathol. 257:186. PubMed Alam A, et al. 2022. Cancer Cell. 40:153. PubMed Huang SSY, et al. 2022. J Cell Mol Med. 26:1714. PubMed Atalis A, et al. 2022. J Control Release. 347:476. PubMed Xu C, et al. 2022. iScience. 25:105123. PubMed Weng S, et al. 2022. Front Immunol. 13:1025931. PubMed Tatsumi N, et al. 2022. STAR Protoc. 3:101845. PubMed Giannou AD, et al. 2023. Immunity. 56:125. PubMed Mallick S, et al. 2023. Transl Res. :. PubMed Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed Denis M, et al. 2023. Front Immunol. 13:1011943. PubMed Labuz DR, et al. 2023. Elife. 12: . PubMed Shen JZ, et al. 2022. Mol Cell. 82:1123. PubMed Zhang H, et al. 2022. J Exp Med. 219:. PubMed Xu H, et al. 2017. EBioMedicine. 10.1016/j.ebiom.2017.03.003. PubMed Lu C, et al. 2019. Cancer Immunol Res. 7:414. PubMed Matsui K, et al. 2015. PLoS One. 10: 0137195. PubMed Clarke F,et al. 2017. PLoS One. 10.1371/journal.pone.0186625. PubMed Vaughan HJ, et al. 2021. Mol Ther Oncolytics. 21:377. PubMed Gruber T, et al. 2020. JCI Insight. 5:00. PubMed Trimaglio G, et al. 2020. Oncoimmunology. 9:1790125. PubMed Souza-Fonseca-Guimaraes F, et al. 2015. Proc Natl Acad Sci U S A. 112:2376. PubMed Rao S, et al. 2017. Cell. 168(3):503-516.e12. PubMed Godbersen-Palmer C, et al. 2020. J Immunol. 204:2973. PubMed Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed Rafiq S, et al. 2018. Nat Biotechnol. 36:847. PubMed Poggio M, et al. 2019. Cell. 177:414. PubMed Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed Leigh N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1502181. PubMed An J,et al. 2017. Sci Rep.. 10.1038/s41598-017-13629-0. PubMed Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed Odeh-Couvertier VY, et al. 2022. Bioeng Transl Med. 7:e10282. PubMed Vanshylla K, et al. 2022. Cell Host Microbe. 30:69. PubMed Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed Reighard SD, et al. 2020. Cell Rep Med. :1. PubMed Lin J, et al. 2017. Sci Rep. 7:41722. PubMed Lord JD, et al. 2018. Clin Immunol. 193:24:00. PubMed Nath PR, et al. 2019. Cancer Immunol Res. 7:1547. PubMed Fallet B, et al. 2020. Cell Rep. 30:1013. PubMed Littwitz-Salomon E, Schimmer S, and Dittmer U. 2017. J Virol. 10.1128/JVI.01122-17. PubMed Zhang X, et al. 2022. Cell Rep. 40:111203. PubMed Trüb M, et al. 2020. J Immunother Cancer. 8:00. PubMed Shiao SL, et al. 2021. Cancer Cell. 39:1202. PubMed Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed Moreno-Fernandez ME, et al. 2018. JCI Insight. 3. PubMed Li D, et al. 2019. J Lipid Res. 60:1503. PubMed Lerrer S, et al. 2021. iScience. 24:103020. PubMed Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed Gehling K, et al. 2022. Life Sci Alliance. 5:. PubMed Nath PR, et al. 2022. Oncoimmunology. 11:2111909. PubMed Kalbasi A, et al. 2020. Sci Transl Med. :12. PubMed Huang SSY, et al. 2021. Biology. 10(8):. PubMed Zeng Y, et al. 2019. Oncotarget. 10:4479. PubMed Fredriksson-Lidman K, et al. 2017. PLoS One. 10.1371/journal.pone.0185509. PubMed Truong AS, et al. 2021. J Clin Invest. 131:. PubMed Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed Burns JC, et al. 2020. eLife. 9:00. PubMed O’Neill R, et al. 2017. J Immunol. 10.4049/jimmunol.1700380. PubMed Harder I, et al. 2022. Cells. 11:. PubMed McVey JC, et al. 2022. iScience. 25:103847. PubMed Smith CA, et al. 2019. JCI Insight. 4. PubMed Den Braanker H, et al. 2021. Front Immunol. 12:768113. PubMed Ganguly S, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:891. PubMed Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed Johnston S, et al. 2021. Elife. 10: . PubMed Pasciuto E, et al. 2020. Cell. 182:625. PubMed Zhang R, et al. 2022. Front Pharmacol. 13:870848. PubMed Graciotti M, et al. 2020. Vaccines (Basel). 8:00. PubMed Capuccini B, et al. 2016. Sci Rep. 6:39258. PubMed Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed Lyle C, et al. 2019. Sci Rep. 9:20257. PubMed Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed Moreno-Fernandez ME, et al. 2021. STAR Protoc. 2:100937. PubMed Wu J, et al. 2021. STAR Protoc. 2:101022. PubMed Georg P, et al. 2022. Cell. 185:493. PubMed Ireland RE, et al. 2022. Viruses. 14:. PubMed Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed Salehi S, et al. 2017. PLoS One. 10.1371/journal.pone.0163614. PubMed Nath PR, et al. 2019. Front Immunol. 9:2985. PubMed Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed Mempin M, et al. 2021. Cancers (Basel). 13:. PubMed Wimmers F, et al. 2021. Cell. 184:3915. PubMed Galván-Peña S, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed Prosser A, et al. 2021. STAR Protoc. 2:100810. PubMed Giles D, et al. 2016. PLoS One. 11: 0149783. PubMed Lacar B, et al. 2016. Nat Commun. 7: 11022. PubMed Grabiec A, et al. 2017. J Allergy Clin Immunol. 10.1016/j.jaci.2017.03.024. PubMed Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed Lee A, et al. 2022. Nat Commun. 13:549. PubMed Zeng Y, et al. 2019. FASEB J. 33:6596. PubMed Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed Zhong W, et al. 2022. Front Immunol. 13:1001255. PubMed Gamradt S, et al. 2021. iScience. 24:103312. PubMed |
|---|
| Biology Area | Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience |
|---|
| Gene ID | NA |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Fixable Dye, Fixable Viability Dye, Dead, Apoptosis |
|---|
